MedTrace Logo

Response Guided Treatment With Direct Acting Anti-Viral Medications for Chronic HCV Infection

NCT03603327 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-02-18

No results posted yet for this study

Summary

To evaluate the efficacy and safety of direct acting anti-viral agents (DAA) therapy in chronically infected Hepatitis C Virus (HCV) patients using an individualized response guided therapy (RGT) model.

Conditions

  • Hepatitis C

Interventions

DRUG

Direct acting anti-viral agents

Standard of care for Hepatitis C treatment

Sponsors & Collaborators

  • Loyola University, Harel Dahari, PhD, mathematical modeling support

    collaborator UNKNOWN

  • Soroka University Medical Center

    lead OTHER

Principal Investigators

  • Ohad Etzion, MD · Soroka UMC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-25
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03603327 on ClinicalTrials.gov